Fog Blog Breast Cancer Update Log:

HERE IS NO. 3 IN THE TOP 5 BREAST CANCER RESEARCH BREAKTHROUGHS OF 2017......Estrogen-Positive Breast Cancer Research .

An estimated 75-80% of breast cancers are estrogen positive (ER+). Anti-estrogen therapy with tamoxifen and/or an aromatase inhibitor is the standard treatment approach for ER+ breast cancer. These drugs work by attaching to a molecule called the estrogen receptor in cancer cells, thereby preventing estrogen from binding to the receptor. Unfortunately, as many as one-third of these cancers eventually become treatment resistant.A novel molecule called ERX-11 was developed and tested on mice and human cancer cells by researchers at UT Southwestern Simmons Cancer Center. The drug works by blocking the estrogen receptor from interacting with the co-regulator proteins that cause a tumor's growth. Researchers believe ERX-1 holds future promise as a first-line breast cancer therapy.